文献速递腹部MR

2017版与2018版LI-RADS在钆塞酸二钠增强MRI诊断肝细胞癌中的诊断效能比较

Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI.
PubMed 文献 · Clin Radiol · 2019-12-16

该研究纳入117例高危患者的137个观察灶(89个肝细胞癌),比较LI-RADS v2017与v2018在钆塞酸二钠增强MRI上的诊断效能。v2018使76.2%(64/84)阈值增长观察灶重分类为亚阈值增长,最终分类仅9例(14%)改变;LR-5/LR-5V联合的敏感度和特异度无显著差异,仅用主要特征时v2018在10-20mm观察灶准确性低于v2017,加入辅助特征后两者相当。

要点

  • v2018将76.2%(64/84)阈值增长观察灶重分类为亚阈值增长,但最终LI-RADS分类仅14%改变。
  • LR-5/LR-5V联合诊断:v2017敏感度64%、特异度87.5%,v2018敏感度58.4%、特异度85.4%,差异无统计学意义。
  • 仅用主要特征时v2018在10-20mm观察灶准确性低于v2017,加入辅助特征后两者相当。

诊断标准与关键数值

  • v2017版与v2018版LI-RADS分类标准:LR-5/LR-5V联合的敏感度64% vs 58.4%、特异度87.5% vs 85.4%,差异均无统计学意义(p>0.05)。
  • 仅用主要特征时LR-4联合LR-5/5V的准确性:v2017为86.1% vs v2018为80.3%(p=0.013),v2018低于v2017。
  • 加入辅助特征后LR-4联合LR-5/5V的准确性:v2017为86.9% vs v2018为86.1%(p=1.00),两者相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To compare the diagnostic performance of the 2017 (v2017) and 2018 versions (v2018) of the Liver Imaging-Reporting and Data System (LI-RADS) for hepatocellular carcinoma (HCC) using gadoxetic acid-enhanced magnetic resonance imaging (Gd-EOB-MRI) and to evaluate the effect in v2018.

MATERIALS AND METHODS: Treatment-naive patients at high-risk for HCC who underwent Gd-EOB-MRI were included. The LI-RADS categories were assigned according to v2017 and v2018. The diagnostic performances were compared between v2017 and v2018 according to the size and combination of imaging features.

RESULTS: A total of 117 patients with 137 observations were identified, including 89 HCCs; 76.2% (64/84) of observations with threshold growth were re-classified as subthreshold growth when using v2018 instead of v2017. The final categories changed in nine (14%) cases. For the combination of LR-5/LR-5V, there were no significant differences in sensitivity and specificity between the two versions (sensitivity, 64% versus 58.4%; specificity, 87.5% versus 85.4%; all p>0.05). For the combination of LR-4 and LR-5/5V, the diagnostic performance of v2018 was inferior to that of v2017 when considering only major features (accuracy, 86.1% versus 80.3%, respectively; p=0.013), particularly in observations measuring 10-20 mm, but was comparable after adding the ancillary features (accuracy, 86.9% versus 86.1%, respectively; p=1.00).

CONCLUSION: In LI-RADS v2018, although a considerable number of observations re-classified subthreshold growth, changes in the assigned categories were insignificant; overall diagnostic performance was comparable to that of v2017, but v2018 might emphasise the value of ancillary features in combination with major features for determining the probability of HCC.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Ko A, Park HJ, Lee ES, et al. Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI. Clin Radiol. 2019. PMID: 31858990. doi:10.1016/j.crad.2019.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。